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β- and α2-adrenoceptor control of 
Vascular Tension and catecholamine 
release in Female normotensive and 
spontaneously hypertensive rats
Torill Berg*
Division of Physiology, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, 
Oslo, Norway
As in humans, young, female, spontaneously hypertensive rats (SHR) have a lower 
blood pressure than male SHR. In male, normotensive rats (WKY), α2- and β1+2-ad-
renoceptors (AR) reciprocally controlled catecholamine release and vascular smooth 
muscle tension. This interaction was malfunctioning in male SHR. The present study 
analyzed if a favorable shift in the α2/β1+2AR interaction may represent an antihyper-
tensive protection in females. Female SHR (early hypertension, 12–14  weeks) and 
age-matched WKY were infused with tyramine (15  min) to stimulate norepinephrine 
(NE) release through the reuptake transporter, consequently preventing reuptake. 
Presynaptic control of vesicular release was therefore reflected as differences in overflow 
to plasma. The released NE increased total peripheral vascular resistance (TPR). The 
results showed that β1>2AR facilitated tyramine-stimulated NE release in both strains, 
also in the presence of α2AR-antagonist (L-659,066). βAR-antagonist (atenolol-β1, ICI-
118551-β2, nadolol-β1+2) had no effect on the increased secretion of epinephrine after 
L-659,066 in WKY, but β1>2AR-antagonist augmented the L-659,066-induced increase 
in the secretion of epinephrine in SHR. Nadolol increased the TPR response to tyramine 
with a greater effect in WKY than SHR, whereas β1or2-selective antagonists did not. One 
βAR-subtype may therefore substitute for the other. When both β1+2AR were blocked, 
α2AR-antagonist still reduced the TPR response in WKY but not SHR. Thus, α2/β1+2AR 
reciprocally controlled catecholamine release, with a particular negative β1AR-influence 
on α2AR-auto-inhibition of epinephrine secretion in SHR. Moreover, in these female rats, 
β1/2AR-independent α2AR-mediated vasoconstriction was seen in WKY but not SHR, 
but β1/2AR-mediated vasodilation downregulated adrenergic vasoconstriction, not only 
in WKY but also in SHR.
Keywords: hypertension, β-adrenoceptors, α2-adrenoceptors, norepinephrine, epinephrine, female rats, 
spontaneously hypertensive rats, total peripheral vascular resistance
inTrODUcTiOn
Blood pressure (BP) in premenopausal women and young spontaneously hypertensive rats (SHR) is 
lower than that in males of the same age (1, 2). In a previous study (3), systolic/diastolic blood pres-
sure (SBP/DBP) in 12–14 weeks old, anesthetized SHR was measured to 183/146 and 108/75 mm Hg 
in males and females, respectively, the latter not significantly different from the 87/61  mm  Hg 
recorded in female normotensive rats [Wistar Kyoto (WKY)] (3). The female SHR at this age may 
FigUre 1 | Presynaptic modulation of vesicular norepinephrine (ne) release studied by the use of tyramine. By reversing the transport through the 
norepinephrine reuptake transporter (NET), tyramine stimulates the release of NE, and through that prevents normal reuptake through NET. The released NE or other 
agonists present will activate presynaptic receptors, which will facilitate [β1/2AR and angiotensin AT1 receptor (AT1R)] or inhibit (α2AR) release of NE from synaptic 
vesicles. This influence will be reflected as differences in the NE overflow to plasma. Arrow—stimulatory action; blunted arrow—inhibitory action; Gs—stimulatory 
G-protein; Gi—inhibitory G-protein; Gq—Gq-protein.
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therefore be classified as prehypertensive, since female SHR of the 
same stock developed a high BP later in life, i.e., 170/129 mm Hg, 
which was not different from the 175/140 mm Hg in male SHR, 
both around 1-year old (3). The mechanism responsible for 
this gender-dependent difference in disease development is not 
known but may involve differences in the control of sympathetic 
nervous system activity and/or sympathetic control of vascular 
tension.
catecholamine release
The release of norepinephrine (NE) from sympathetic nerve end-
ings is controlled by a reciprocal action of presynaptic α2AR and 
βAR, which inhibit and facilitate release, respectively (Figure 1). 
The α2AR-mediated auto-inhibition of release of NE and also 
epinephrine was functional in male WKY but not in the male 
SHR (4, 5). However, α2AR clearly inhibited release of both 
catecholamines in the female SHR (3). In male rats, both β1- and 
β2AR-facilitated release (5), and strain-related differences in the 
interaction between α2AR and β1/2AR were observed (6). The role 
of β1+2AR in the control of catecholamine release and their inter-
action with the α2AR has not been studied in the female SHR.
Vascular Tension
Release of NE from peripheral sympathetic nerves evokes 
vasoconstriction by activating α1-adrenoceptors (AR) in the vas-
cular smooth muscle cells (VSMC). This response is modulated 
reciprocally by βAR and α2AR, activating stimulatory (Gs) and 
inhibitory (Gi) G-proteins, respectively, opposing and enhancing 
the α1AR-mediated vasoconstriction. Thus, α2AR-antagonist 
lowered the rise in total peripheral vascular resistance (TPR) 
in response to endogenous release of NE in 12- to 14-week-old 
male WKY (4), and this reduction was in part counteracted by 
β1/2/1+2AR-antagonists (6). Dysfunctional α2AR has been observed 
in the male SHR (7, 8), and α2AR-antagonist had little effect on the 
rise in TPR during endogenous NE release in 12- to 14-week-old 
male SHR (4). Moreover, in male SHR, β1+2AR-mediated 
vasodilatation did not oppose NE-induced vasoconstriction even 
in the presence of α2AR-antagonist (6). However, in female SHR, 
α2AR-antagonist lowered the TPR response, although not equally 
efficient as in female WKY (3, 4). It is not known if the vasodila-
tory effect of α2AR-antagonist in female SHR in this early stage of 
hypertension is due to a more functional βAR-mediated vasodila-
tation than in male SHR. A gender-dependent difference in the 
β-AR control of vascular tension has been described in humans. 
In young men, muscle sympathetic nerve activity (MSNA) was 
correlated to TPR but inversely correlated to cardiac output (CO). 
Similar correlations were not observed in young women (9). This 
difference was attributed to βAR-mediated vasodilatation, since 
a positive correlation between MSNA and TPR was observed also 
in the women in the presence of the non-selective βAR-antagonist 
propranolol (10). An improved contribution from vasodilatory 
βAR may lower TPR. Since a high TPR is a hallmark of hyperten-
sion, a βAR-mediated downregulation of TPR may play a role in 
preserving a lower BP in the female gender.
The angiotensin AT1 receptor (AT1R) antagonist losartan 
lowered the TPR response to stimulated endogenous release of NE 
in male WKY but not SHR (11), suggesting that VSMC AT1R-
signaling may depend on functional α2AR-Gi and/or βAR-Gs acti-
vation. Moreover, in male rats, losartan greatly increased the TPR 
and MBP responses to NE release when combined with atenolol, 
particularly in WKY (5). It is not known if this occurs also in female 
rats. Since losartan and atenolol are often used in combination to 
treat hypertension, this interaction may be of great importance for 
the outcome in situations with enhanced NE release such as during 
myocardial ischemia (12). A possible gender-dependent difference 
in this interaction may therefore be of clinical importance.
The purpose of the present study was therefore to determine 
the impact of β1and2AR on catecholamine release and vascular 
FigUre 2 | an overview of the experimental design. PBS—sham injection with vehicle. L-659,066—peripherally restricted and non-selective α2AR-antagonist. 
Atenolol and metoprolol—peripherally restricted and not restricted β1AR-antagonist, respectively. ICI-118551—not restricted β2AR-antagonist. Nadolol—peripherally 
restricted β1+2AR-antagonist. Losartan—angiotensin AT1 receptor antagonist. Tyramine—stimulates reverse transport of norepinephrine through the norepinephrine 
reuptake transporter.
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tension in female WKY and SHR. The second goal was to analyze 
the interaction between β1and2AR and α2AR and between the β1AR 
and AT1R in female rats. Differences between the present results 
on female rats compared to that previously observed in male rats 
will be discussed.
MaTerials anD MeThODs
experimental Procedure
The rats, i.e., WKY and SHR (Okamoto, SHR/NHsd strain) were 
originally supplied by formally legacy Harlan, now Envigo RMS, 
Bicester, England, and bred in-house. The rats included in this 
study were all 12- to 14-week-old females (67 WKY, 181 ± 2 g b.w., 
13.0 ± 0.1 weeks; 67 SHR, 178 ± 1 g b.w., 12.9 ± 0.1 weeks). The 
rats were housed on 12/12 h light/dark cycles and were allowed 
food (conventional rat chow diet with 0.7% NaCl) and water ad lib 
until the time of the experiment. The rats were anesthetized with 
pentobarbital (70–75 mg/kg, i.p.) and tracheotomised. SBP and 
DBP were monitored through a catheter in the femoral artery, also 
used to record heart rate (HR) before the rats were connected to a 
positive-pressure ventilator. After thoracotomy, entering through 
the third intercostal space, CO (CO = minus cardiac flow) and 
HR were recorded by a flow probe on the ascending aorta, con-
nected to a T206 Transonic Flow meter (Transonic Systems Inc., 
Ithaca, NY, USA). Mean arterial BP (MBP = SBP–DBP/3 + DBP) 
and TPR (MBP/CO) were calculated. The rats were ventilated 
with air throughout the experiment. Body temperature was main-
tained at 37–38°C by external heating, guided by a thermo sensor 
inserted inguinally about 1–2 cm into the abdominal cavity. All 
drugs were dissolved in phosphate-buffered saline (PBS = 0.01 M 
Na-phosphate, pH 7.4, 0.14 M NaCl) and administered through a 
catheter in the femoral vein. When all surgery was completed, the 
arterial catheter was flushed with 0.1 ml PBS containing 500 IU 
heparin/ml. The rats were injected with PBS as needed to stabilize 
BP and then allowed a resting period of 10 min.
experimental Design
All rats were infused with tyramine (1.26 µmol/min/kg, 15 min). 
Tyramine stimulates NE release by reversing the transport 
through the NE reuptake transporter (NET), consequently block-
ing reuptake (Figure 1). Activation of the presynaptic receptors 
by the released NE and/or other agonists/antagonists present 
will alter the vesicular release of NE, and this modification will 
be reflected as differences in the overflow of NE to plasma, as 
previously documented in detail (4, 13). The action of tyramine 
is peripherally restricted, i.e., tyramine does not cross the blood–
brain barrier (14). Tyramine does not stimulate the secretion 
of epinephrine from the adrenal glands. However, the trauma 
induced by the surgical procedure activated some secretion of 
epinephrine, also subjected to receptor-mediated release control 
(3, 4, 13). Removal of the adrenal glands did not alter the plasma 
NE concentration, indicating that tyramine stimulated the release 
of NE from sympathetic nerves rather than from NE-producing 
cells in the adrenal medulla (5). The tyramine-induced NE 
release activated a cardiovascular response. The amount of cat-
echolamines released into the synapse and into the circulation 
was most likely higher than that needed for a full cardiovascular 
response, and thus independent of drug-induced differences in 
catecholamine release. Antagonist-induced changes in the TPR 
response therefore reflected largely changes due to inhibition of 
the postsynaptic receptors.
A flowchart of the experimental design is shown in Figure 2. 
Control rats were pretreated with PBS, and the tyramine infusion 
was started 10 min later. To answer the questions if β1AR and/
or β2AR stimulated catecholamine release and/or opposed the 
NE-induced rise in TPR, the PBS sham injection was substituted 
with either β1AR-selective antagonists, i.e., the peripherally 
restricted atenolol (5.6 µmol/kg) or the not restricted metoprolol 
(8.8  µmol/kg, β1), or the β2AR-selective antagonist ICI-118551 
(initial dose of 1 µmol/kg, followed by 0.3 µmol/kg/min through-
out the experiment) (15). To test for an additive effect of the 
TaBle 1 | The plasma concentration of norepinephrine and epinephrine at the end of the tyramine-infusion period in female rats.
normotensive rats (WKY) spontaneously hypertensive rats (shr)
norepinephrine (nM) epinephrine (nM) norepinephrine (nM) epinephrine (nM)
PBS + tyramine 24.0 ± 1.0 2.8 ± 1.1 32.8 ± 1.7* 2.2 ± 0.6
Metoprolol (β1AR) + tyramine 9.7 ± 1.2† 0.9 ± 0.3 16.5 ± 2.2*,† 6.9 ± 1.5*,†
Atenolol (β1AR) + tyramine 10.9 ± 0.6† 1.2 ± 0.6 15.9 ± 1.9*,† 5.2 ± 1.2*,†
ICI-118551 (β2AR) + tyramine 15.5 ± 1.5†,├ 4.0 ± 1.1├ 24.0 ± 2.5*,†├ 10.4 ± 2.8†
Nadolol (β1+2AR) + tyramine 13.8 ± 0.6†,├ 1.5 ± 0.7 14.7 ± 0.8† 5.9 ± 1.3*,†
L-659,066 (α2AR) + tyramine 34.4 ± 3.0† 15.3 ± 5.6† 45.6 ± 3.7*,† 15.4 ± 2.6†
Atenolol + L-659,066 + tyramine 14.7 ± 0.8†,‡,§ 8.9 ± 1.5† 33.8 ± 2.6*,‡,§ 41.8 ± 7.6*,†,‡,§
ICI-118551 + L-659,066 + tyramine 20.0 ± 1.0†,‡,§,├ 13.4 ± 2.2† 30.8 ± 3.6*,‡ 23.4 ± 4.1†,§,├
Nadolol + L-659,066 + tyramine 13.1 ± 0.7†,‡ 13.8 ± 3.8†,§ 37.4 ± 3.7*,§ 41.3 ± 11.9†,‡,§
Losartan + atenolol + tyramine 10.9 ± 1.0† 1.7 ± 1.1 20.7 ± 1.5*,† 9.1 ± 2.1†,*
Differences were detected as indicated between corresponding WKY and SHR groups (* after SHR values), and within each strain between the controls and the experimental groups 
(†), between corresponding groups pretreated with L-659,066 and βAR-antagonist + L-659,066 (‡), between the groups pretreated with βAR-antagonist alone and corresponding 
βAR-antagonist + L-659,066 (§), between corresponding groups given β1AR-antagonist and β2 or 1+2AR-antagonist (├), or between groups given β1AR-antagonist + L-659,066 and  
β2 or 1+2AR-antagonist + L-659,066 (├), and between corresponding groups given atenolol and losartan + atenolol (none detected). *,†,‡,§,├P ≤ 0.05.
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β1AR and the β2AR, the rats were pretreated with the peripherally 
restricted β1+2AR-selective antagonist nadolol (8.5 µmol/kg) (15).
To test the influence of β1AR and β2AR on α2AR-mediated 
inhibition of catecholamine release and TPR, the rats were pre-
treated with atenolol, ICI-118551, or nadolol as above, followed 
10  min later by the non-selective α2AR-antagonist L-659,066, 
which does not cross the blood–brain barrier (4, 13, 16).
To test for an interaction between β1AR and AT1R, rats were 
pretreated with the AT1R-antagonist losartan (79 µmol/kg) (17), 
followed 10 min later by atenolol and tyramine as above.
salivation
Salivation does not occur spontaneously in anesthetized rats 
but was stimulated here by tyramine. Saliva was collected with 
a pipette from the oral cavity throughout the tyramine-infusion 
period. Saliva volume was estimated by weight.
Measurement of Plasma catecholamines
Blood (1.5 ml) was collected from the arterial catheter after the 
tyramine-observation period, but without discontinuing the 
tyramine infusion (Figure 2). The blood was sampled into tubes 
containing 40 µl 0.2 M glutathione and 0.2 mol/l ethylene glycol-
bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA). 
Plasma was stored at −80°C until the catecholamine concentrations 
were determined using 400 µl plasma and the “5000 Reagent kit for 
HPLC analysis of Catecholamines in plasma” from Chromsystems 
GmbH, Munich, Germany, as previously described (6).
Drugs
L-659,066 and losartan were kindly supplied by Merck, Sharp 
and Dohme Labs, Rahway, NJ, USA, ICI-118551 was obtained 
from ICI-Pharma, Cheshire, UK, and pentobarbital from The 
Norwegian National Hospital, Oslo, Norway. The remaining 
drugs were from Sigma Chemical Co., St. Louis, MO, USA.
statistical analyses
Results are presented as mean values ± SEM. The cardiovascular 
data were averaged every min in all experiments, but every seven 
heartbeats (five samplings) for the starting BPs and HR. The 
cardiovascular response curves to tyramine were analyzed using 
Repeated Measures Analyses of Variance and Covariance, first as 
over-all tests including all groups or all groups within each strain, 
and subsequently for each group separately or between groups. 
When significant responses, differences, and/or interactions were 
indicated, significant responses were located at specific times 
using one-sample Student’s t-tests. Differences between groups 
at the same times were identified using two-sample Student’s 
t-tests for parametric data and Kruskal–Wallis tests for non-
parametric data. For the MBP- and TPR response curves, these 
ad hoc analyses were done at the time of the TPR-peak response 
in the control groups, i.e., at 4 min, and also at 15 min. For the 
HR and CO responses, the ad  hoc analyses were performed 
only at 15 min. The plasma catecholamine concentrations were 
first analyzed using two-way ANOVA, and the cardiovascular 
baselines, the effect of pretreatment and the tyramine-induced 
salivation by one-way ANOVA. Group- and strain-related dif-
ferences were subsequently located by two-sample Student’s 
t-tests for parametric data, or, in the presence of outliers, by 
non-parametric Kruskal–Wallis tests. The P-value was for all 
tests and each step adjusted according to Bonferroni, except for 
differences in the effect of pretreatment, plasma catecholamine 
concentrations, and salivation, where P ≤  0.05 was considered 
significant. Six to twelve rats were included in each group, based 
on sample power calculations using previous data from similar or 
related experiments. The rats in the WKY and SHR control and 
L-659,066-treated groups were in part the same as in a previous 
study (3), run intermittently with the present study.
resUlTs
The role of βar and α2ar in the control 
of catecholamine release in Female rats
Norepinephrine
As before (3), the plasma concentration of NE at the end of the 
tyramine-infusion period was greater in SHR than in WKY 
(P = 0.001) (Table 1). The β1AR-antagonists atenolol and meto-
prolol reduced NE overflow to about 40–45% in both strains 
5Berg Gender and AR in Hypertension
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(P <  0.001), whereas the β2AR-antagonist ICI-118551 reduced 
the plasma concentration to 65–70% (P ≤  0.013). The β1+2AR-
antagonist nadolol reduced the plasma NE concentration to 58 
and 45% in WKY and SHR, respectively (P < 0.001). The effect of 
ICI-118551 was less than that following β1AR-antagonists in both 
strains and in WKY also that of nadolol (P ≤ 0.015). As previously 
documented (3), the α2AR-antagonist L-659,066 increased the 
NE overflow in both strains (P = 0.026 and P < 0.001 in WKY and 
SHR, respectively). L-659,066 eliminated only in part the reduc-
tion induced by atenolol and ICI-118551 in WKY (P =  0.006 
and 0.025 compared to βAR-antagonist alone), and the plasma 
concentration remained less than that in the controls (P ≤ 0.004). 
The inhibitory effect of atenolol on the L-659,066-induced 
increased NE release in WKY was greater than that of ICI-118551 
(P = 0.003) but was not different from that of nadolol. In SHR, 
L-659,066 abolished the effect of βAR antagonist (P = NS com-
pared to the controls) but remained less than that after L-659,066 
alone when combined with atenolol or ICI-118551 (P ≤ 0.013). 
NE overflow in the nadolol + L-659,066-treated SHR was clearly 
higher than that after nadolol alone (P = 0.006) but not different 
from that after L-659,066 alone or that in the control group.
Atenolol reduced the plasma NE concentration also when 
combined with losartan in both strains of female rats (P = NS 
compared to atenolol alone).
Epinephrine
A strain-related difference was not detected in the plasma epi-
nephrine concentration in the control groups at the end of the 
experimental period (Table  1). β1-, β2-, and β1+2AR-antagonist 
alone had little effect on the plasma epinephrine concentra-
tion in WKY but slightly increased the concentration in SHR 
(P ≤ 0.044). L-659,066 increased the secretion of epinephrine in 
both strains (P ≤ 0.002). Atenolol, ICI-118551, and nadolol did 
not alter the enhancing effect of L-659,066 in WKY. However, 
atenolol and nadolol potentiated the effect of L-659,066 in SHR 
(P ≤ 0.039), whereas the increase observed after ICI-118551 was 
not statistically significant. Losartan + atenolol slightly increased 
the secretion of epinephrine in SHR.
cardiovascular Baselines in Female WKY 
and shr and the effect of Pretreatment
Starting BP and HR, recorded before the rats were connected 
to the respirator, were greater in the female SHR than in the 
female WKY (SBP/DBP/MBP = 138 ± 5/103 ± 4/115 ± 4 and 
85 ± 3/60 ± 3/69 ± 3 mm Hg and HR = 373 ± 7 and 300 ± 9 bpm 
in SHR and WKY, respectively, P < 0.001, all groups included). 
As previously discussed (3, 4), SHR of both genders were more 
sensitive to the reduced venous return to the right heart during 
positive-pressure ventilation than WKY. Thus, after the rats were 
connected to the ventilator, surgery completed and the rats had 
been pretreated with PBS, i.e., prior to tyramine, strain-related 
differences in MBP and HR were no longer observed (Table 2). 
At this time, CO was lower, and TPR higher in SHR compared to 
WKY (P < 0.001).
The cardiovascular response to pretreatment is shown in 
Table  2. The major findings were that L-659,066 and ateno-
lol + L-659,066 reduced TPR (P ≤ 0.024) and losartan + atenolol 
reduced both MBP and TPR (P ≤ 0.005) in WKY, whereas TPR 
was slightly higher after ICI-118551 or nadolol (P ≤ 0.033) in this 
strain. In SHR, MBP was reduced by ICI-118551 + L-659,066, 
nadolol  +  L-659,066, and losartan  +  atenolol, and TPR by 
atenolol + L-659,066 (P ≤ 0.021). Baseline HR was reduced in all 
groups given βAR antagonist, alone or combined with L-659,066 
(P ≤ 0.044) in both strains, except in the WKY ICI-118551 and 
losartan  +  atenolol groups. Nadolol and losartan  +  atenolol 
reduced also CO in SHR (P < 0.001).
The effect of βar-antagonists on the 
cardiovascular response to Tyramine  
and Their interaction with α2ar-
antagonist in Female rats
As previously documented (3), the tyramine-stimulated release 
of NE induced a rise in TPR, which reached a peak after 4 min 
in both strains (Figures  3 and 4), and a sustained increase in 
HR (Figure 5), CO (Figure 6), and MBP (Figure 7). The TPR 
response to tyramine was transient in WKY, but sustained in 
SHR, and was higher in SHR than in WKY at the end of the 
tyramine-infusion period (P ≤ 0.015).
The effect of βAR- and α2AR-antagonists on the TPR response 
throughout the tyramine-infusion period is shown in Figure 3 and 
on the immediate TPR-peak response as bar graphs in Figure 4. 
Nadolol (P ≤ 0.007), but not metoprolol, atenolol, or ICI-118551 
(P =  NS), increased the immediate and late TPR response to 
tyramine in both WKY and SHR. The effect of nadolol during 
the immediate response to tyramine was greater in WKY than 
in SHR (P = 0.016). L-659,066 changed the vasoconstriction to a 
vasodilatory response in WKY and eliminated the vasoconstric-
tion in SHR. The L-659,066-dependent vasodilatation in WKY 
was reversed to vasoconstriction after additional pretreatment 
with atenolol but remained lower than that in the WKY control 
group (P ≤  0.008 compared to the L-659,066 or atenolol-only 
groups or the controls, at 4 min). After pretreatment with ICI-
118551 +  L-659,066, the vasodilatory response was eliminated 
but not changed to vasoconstriction (P ≤  0.007 compared to 
the L-659,066- or ICI-118551-only groups or the WKY control 
group, at 4 min). After nadolol + L-659,066, the immediate and 
late TPR response to tyramine in WKY was lower than that after 
nadolol alone (P ≤ 0.011) and not different from that in the con-
trols, but higher than that after atenolol/ICI-118551 + L-659,066 
and after L-659,066 alone (P ≤ 0.016). In SHR, the TPR response 
to tyramine after pretreatment with atenolol + L-659,066 or ICI-
118551 + L-659,066 was not different from that after L-659,066 
alone. The elevated TPR response after nadolol was not influenced 
by additional pretreatment with L-659,066 in SHR, and ΔTPR in 
SHR pretreated with nadolol + L-659,066 was higher than that 
in the controls and after L-659,066 alone and after atenolol/ICI-
118551 + L-659,066 (P ≤ 0.001).
Losartan + atenolol strongly increased the TPR-peak response 
to tyramine in female WKY (P = 0.008) but reduced the response 
in SHR (P = 0.004) (Figure 8).
A strain-related difference was not observed in the tyramine-
induced tachycardia (P =  NS) (Figure  5). The HR response to 
tyramine was clearly reduced in all groups where pretreatment 
TaBle 2 | cardiovascular baselines after pretreatment, i.e., prior to tyramine, in female rats. The response to pretreatment is shown below in parenthesis.
Pretreatment normotensive rats (WKY) spontaneously hypertensive rats (shr)
MBP (mm hg) hr (bpm) cO (ml/min) TPr (mm hg/ml/min) MBP (mm hg) hr (bpm) cO (ml/min) TPr (mm hg/ml/min)
PBS 64 ± 3  
(−3 ± 2)
356 ± 12  
(0 ± 6)
22 ± 1  
(1 ± 0)
2.9 ± 0.1  
(−0.2 ± 0.1)
58 ± 3  
(−16 ± 5)*
365 ± 8  
(−32 ± 5)*
14 ± 1*  
(−1 ± 0)*
4.3 ± 0.4*  
(−0.7 ± 0.3)
Atenolol 54 ± 3†  
(−5 ± 3)
324 ± 6†  
(−23 ± 8)†
20 ± 1  
(−1 ± 1)
2.8 ± 0.1  
(−0.1 ± 0.0)
63 ± 3  
(−18 ± 7)
350 ± 14  
(−60 ± 12)†
12 ± 1  
(−2 ± 1)
5.4 ± 0.2†  
(−0.4 ± 0.3)
Metoprolol 67 ± 3  
(−6 ± 3)
331 ± 6  
(−32 ± 7)††
22 ± 2  
(−1 ± 1)
3.2 ± 0.3  
(−0.2 ± 0.2)
55 ± 3  
(−17 ± 3)
301 ± 5††  
(−84 ± 11)††
13 ± 1  
(−1 ± 1)
4.2 ± 0.2  
(−1.3 ± 0.6)
ICI-118551 55 ± 4  
(−1 ± 3)
334 ± 12  
(−20 ± 8)
22 ± 1  
(−2 ± 1)
2.5 ± 0.2  
(0.1 ± 0.1)†
50 ± 4  
(−20 ± 6)
318 ± 10††  
(−65 ± 11)†
15 ± 1  
(−3 ± 1)
3.4 ± 0.1†  
(−0.6 ± 0.3)
Nadolol 55 ± 4  
(−3 ± 4)
337 ± 6  
(−21 ± 7)†
20 ± 2  
(−2 ± 1)†
3.0 ± 0.3  
(0.3 ± 0.2)†
53 ± 4  
(−39 ± 10)
315 ± 13†  
(−92 ± 15)††
13 ± 0  
(−3 ± 1)†
4.2 ± 0.4  
(−1.5 ± 0.4)
L-659,066 54 ± 3  
(−9 ± 2)
360 ± 7  
(−5 ± 4)
24 ± 2  
(−1 ± 0)
2.3 ± 0.3†  
(−0.3 ± 0.1)
57 ± 6  
(−25 ± 4)
347 ± 8  
(−34 ± 6)
12 ± 1  
(−4 ± 1)
5.3 ± 1.5  
(0.2 ± 0.9)
Atenolol + L-659,066 48 ± 2†  
(−12 ± 4)
339 ± 5  
(−29 ± 9)†
23 ± 1  
(0 ± 1)
1.9 ± 0.1†  
(−0.7 ± 0.1)†
54 ± 4  
(−28 ± 5)
303 ± 8††  
(−88 ± 6)††
13 ± 1  
(−1 ± 1)
3.4 ± 0.3  
(−0.9 ± 0.2)
ICI-118551 + L-659,066 48 ± 5†  
(−5 ± 2)
333 ± 11  
(−24 ± 9)†
21 ± 2  
(0 ± 1)
2.3 ± 0.1†  
(−0.6 ± 0.1)
42 ± 3††  
(−20 ± 3) 
283 ± 13††  
(−85 ± 5)††
15 ± 1  
(−2 ± 1)
4.4 ± 0.4  
(−1.7 ± 0.4)
Nadolol + L-659,066 58 ± 3  
(1 ± 1)
334 ± 7  
(−25 ± 5)††
24 ± 1  
(2 ± 1)
2.5 ± 0.2  
(−0.1 ± 0.1)
42 ± 2††  
(−26 ± 10)
317 ± 10††  
(−99 ± 17)††
15 ± 2  
(−3 ± 1)
3.3 ± 0.2†  
(−1.0 ± 0.4)
Losartan + atenolol 54 ± 1††  
(−18 ± 3)††
345 ± 10  
(−15 ± 6)
27 ± 5  
(2 ± 1)
2.2 ± 0.3††  
(−0.9 ± 0.2)††
39 ± 1††  
(−36 ± 5)†
291 ± 5††  
(−106 ± 11)††
9 ± 1††  
(−5 ± 1)††
4.5 ± 0.3  
(−0.9 ± 0.4)
Comparisons were made between the WKY and SHR controls (* after SHR values) and between the PBS control and the experimental groups within each strain (†). *P ≤ 0.0125, †P ≤ 0.05, ††P ≤ 0.0056.
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FigUre 3 | The total peripheral vascular resistance (TPr) response to tyramine-induced norepinephrine release in female normotensive (WKY) and 
spontaneously hypertensive rats (shr). The rats were pretreated with β1- (metoprolol and atenolol), β2- (ICI-118551), β1+2AR- (nadolol) or α2AR- (L-659,066) 
antagonists, alone or combined, as indicated by the symbol legends. Baselines prior to tyramine are shown in Table 2. Significant responses (one-sample Student’s 
t-tests, * within symbol) and differences between the control and experimental groups (two-sample Student’s t-tests, * in brackets) were located at 4 min (peak 
response, please see Figure 4) and at 15 min (brackets right of curves). Comparisons were also made between βAR-antagonist alone and the L-659,066 + βAR-
antagonist groups. *P ≤ 0.025 for one- and two-sample Student’s t-tests after curve evaluations using Repeated Measures Analyses of Variance and Covariance 
(see Materials and Methods).
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contained a β1AR-antagonistic component but was not influenced by 
the β2-selective antagonist ICI-118551. L-659,066 alone had no effect 
on the tyramine-induced tachycardia, and L-659,066 did not alter 
the effect of βAR-antagonist on this response. The tachycardia after 
losartan + atenolol was not different from that after atenolol alone.
Tyramine also increased CO, and with a greater effect in 
female WKY than in female SHR (Figure 6). However, due to the 
lower baseline in SHR, the strain-related difference was not seen 
when the increase was expressed in percent of baseline (ΔCO 
after 15 min = 64 ± 7 and 64 ± 8% in WKY and SHR, respectively, 
P = NS). The tyramine-induced rise in CO was reduced in both 
strains after nadolol alone and after atenolol/ICI-118551/nado-
lol + L-659,066 (P ≤ 0.01 at 15 min).
The rise in MBP at the end of the tyramine-infusion period 
was slightly higher in SHR than in WKY (P = 0.003) (Figure 7). 
The MBP response in WKY was greatly increased after nadolol 
(P  <  0.001), and atenolol and metoprolol slightly increased 
the late MBP response in this strain. The βAR antagonists had 
no significant effect on the MBP response in SHR. L-659,066, 
alone or combined with atenolol or ICI-118551, reduced the 
MBP response throughout the infusion period in both strains 
(P ≤ 0.006). The enhanced MBP response after nadolol in WKY 
was eliminated by additional pretreatment with L-659,066 
(P < 0.001) and was no longer different from that in the WKY 
control group. Losartan +  atenolol slightly enhanced the MBP 
response to tyramine in WKY, whereas losartan  +  atenolol 
reduced the initial response in SHR.
The role of βar and α2ar in the  
Tyramine-induced salivation
Tyramine stimulated salivary secretion. Salivation was 
abolished in all groups pretreated with β1AR-antagonist or 
nadolol, reduced or eliminated after ICI-118551  +  L-659,066 
and nadolol + L-659,066, but was not influenced by β2-selective 
antagonist alone (Table 3).
DiscUssiOn
The main findings in the present study on female rats were that 
β1>2AR facilitated tyramine-stimulated NE release in WKY 
and SHR, whereas β1>2AR opposed α2AR auto-inhibition of 
epinephrine secretion in SHR but not WKY. Second, a strong 
β1+2AR-mediated vasodilatation counteracted NE-induced vaso-
constriction in female WKY. β1+2AR-antagonist counteracted 
NE-induced vasoconstriction also in the female SHR, although 
less than that in WKY. α2AR-antagonist still lowered the TPR 
response to tyramine in the presence of β1+2AR-antagonist in 
WKY but not in SHR.
control of catecholamine release in 
Female rats and a comparison with That 
Previously Observed in Male rats
Norepinephrine
Tyramine-stimulated overflow of NE in female rats was higher 
in SHR than in WKY (present study), similar to that previously 
observed in male rats (5, 6). As in male rats (5), β1AR efficiently 
facilitated NE release in both strains of female rats. This was con-
cluded since atenolol and metoprolol both reduced the overflow 
of NE to plasma by 50–60%. Atenolol, unlike metoprolol, does 
not cross the blood–brain barrier, but the influence of the two 
antagonists on NE overflow did not differ. The effect therefore 
appeared to be peripheral, most likely involving presynaptic β1AR 
which facilitated the release of NE, as previously documented in 
detail in male rats (5).
ICI-118551 reduced the tyramine-induced NE overflow in both 
strains in female rats, demonstrating that also β2AR facilitated NE 
FigUre 4 | Bar graph of the total peripheral vascular resistance 
(TPr)-peak response to tyramine in the experiments shown in 
Figure 3. The female normotensive (WKY) and spontaneously hypertensive 
rats (SHR) were pretreated with β1- (metoprolol and atenolol), β2- (ICI-
118551), β1+2AR- (nadolol) or α2AR- (L-659,066) antagonists, alone or 
combined, as indicated by the symbol legends. Significant responses  
(* within column) and differences between groups (two-sample Student’s 
t-tests, * in brackets) were located as indicated. Comparisons were made 
between the control and the experimental groups, between corresponding 
groups given L-659,066 or βAR-antagonist alone and the L-659,066 + βAR-
antagonist groups and between the nadolol + L-659,066 and 
β1/2AR + L-659,066 groups. Please notice the difference in the scale in the 
two graphs. *P ≤ 0.025 tests after curve evaluations using Repeated 
Measures Analyses of Variance and Covariance (see Materials and Methods).
FigUre 5 | The heart rate (hr) response to tyramine-induced 
norepinephrine release in female normotensive (WKY) and 
spontaneously hypertensive rats (shr). The rats were pretreated with 
β1- (metoprolol and atenolol), β2- (ICI-118551), β1+2AR- (nadolol), α2AR-  
(L-659,066) or angiotensin AT1 receptor antagonists, alone or combined, as 
indicated by the symbol legends. Baselines prior to tyramine are shown in 
Table 2. The change in HR after 15 min was significant in all groups 
(one-sample Student’s t-tests, not indicated). Significant differences between 
the control and experimental groups (two-sample Student’s t-tests, * in 
brackets right of curves) were located at 15 min as indicated. *P ≤ 0.05 after 
curve evaluations using Repeated Measures Analyses of Variance and 
Covariance (see Materials and Methods).
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release. This was similar to that previously seen in male rats (5). 
The effect of the β2AR-antagonist was less than that after β1AR-
antagonist in female WKY and SHR (present study), as in the 
male WKY (5), but not in male SHR where the two antagonists 
had the same effect (5). The greater effect of atenolol compared to 
ICI-118551 was likely to reflect that tyramine activated massive 
release of NE. NE was therefore present in a higher concentration 
in the area around the presynaptic receptors than epinephrine, 
and NE has the same affinity for the β1AR as epinephrine (18). 
Pretreatment with the β1+2AR-antagonist nadolol demonstrated 
that the two βAR did not have an additive effect in female WKY 
or SHR, similar to that previously observed in male rats (6). One 
βAR-subtype therefore appeared to substitute for the other in 
both genders and in both strains.
α2AR-mediated auto-inhibition of release was observed 
in female rats of both strains, demonstrated by the increased 
tyramine-induced overflow of NE to plasma after pretreatment 
with L-659,066. This differed from that previously observed in 
male rats, where L-659,066 increased the plasma NE concentration 
in WKY but not significantly in SHR (4). In the presence of 
L-659,066, β1-, β2-, and β1+2AR-antagonist still reduced NE over-
flow in both strains in the female rats, although apparently with a 
greater effect in WKY than in SHR. Also this observation differed 
from that seen in male rats, where ICI-188551 and nadolol reduced 
NE overflow in male WKY when combined with L-659,066, 
whereas atenolol did not (6), indicating that α2AR-signaling was 
a required substrate for β1AR-mediated stimulation of release in 
the male WKY. However, in male SHR, the presence of β1- but not 
β2AR-antagonist restored α2AR function, i.e., L-659,066 clearly 
increased NE overflow in the presence of atenolol or nadolol but 
not ICI-11855 (6). β1AR-mediated facilitation of release therefore 
opposed α2AR-mediated inhibition of NE release in the male 
but not in the female SHR. This observation may explain the 
dysfunctional α2AR-auto-inhibition of NE release in male SHR. 
The β1AR-mediated facilitation of release was not influenced by 
presynaptic release-stimulating AT1R (Figure 1) in female rats 
of either strain (present study), similar to that previously seen in 
male rats (5).
FigUre 7 | The MBP response to tyramine-induced norepinephrine 
release in female normotensive (WKY) and spontaneously 
hypertensive rats (shr). The rats were pretreated with β1- (metoprolol and 
atenolol), β2- (ICI-118551), β1+2AR (nadolol), α2AR- (L-659,066) or angiotensin 
AT1 receptor antagonists, alone or combined, as indicated by the symbol 
legends. Baselines prior to tyramine are shown in Table 2. The change in 
MBP at 4 min, i.e., at the total peripheral vascular resistance (TPR)-peak 
response (dotted vertical lines), and at 15 min was significant in all groups 
(one-sample Student’s t-tests, not indicated). Significant differences between 
the control and experimental groups were located at the TPR-peak response 
and 15 min as indicated (two-sample Student’s t-tests, * in brackets left and 
right of curves, respectively). *P ≤ 0.025 after curve evaluations using 
Repeated Measures Analyses of Variance and Covariance (see Materials and 
Methods).
FigUre 6 | The cardiac output (cO) response to tyramine-induced 
norepinephrine release in female normotensive (WKY) and 
spontaneously hypertensive rats (shr). The rats were pretreated with 
β1- (metoprolol and atenolol), β2- (ICI-118551), β1+2AR- (nadolol), α2AR- (L-
659,066) or angiotensin AT1 receptor antagonists, alone or combined, as 
indicated by the symbol legends. Baselines prior to tyramine are shown in 
Table 2. The change in CO after 15 min was significant in all groups 
(one-sample Student’s t-tests, not indicated). Significant differences between 
the control and the experimental groups were located at 15 min as indicated 
(two-sample Student’s t-tests, * in brackets right of curves). *P ≤ 0.05 after 
curve evaluations using Repeated Measures Analyses of Variance and 
Covariance (see Materials and Methods).
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Epinephrine
The secretion of epinephrine from the adrenal glands was not 
activated by tyramine but by the trauma induced by the experi-
ment itself (19). The control of this secretion was dominated 
by α2AR-auto-inhibition in both strains in the female rats. This 
conclusion was based on the fact that L-659,066 increased the 
secretion of epinephrine in both strains, whereas the βAR-
antagonists alone had no effect in WKY and slightly increased 
the concentration in SHR. In the male rats, a significant α2AR-
auto-inhibition of epinephrine secretion was regularly seen in 
WKY and occasionally in SHR (4, 6, 11). However, atenolol, ICI-
118551, and nadolol potentiated the effect of the α2AR-antagonist 
in the female SHR (present study) similar to that seen in male 
WKY and SHR (6), in general with a greater effect of the β1- than 
the β2AR-antagonist and with a greater increase in the plasma 
epinephrine concentration in SHR than in WKY. However, none 
of the βAR-antagonists potentiated α2AR function in the female 
WKY. Atenolol combined with AT1R-antagonist had no effect on 
the secretion of epinephrine. It was therefore concluded that βAR, 
with a greater effect of the β1- than the β2-subtype, opposed α2AR 
auto-inhibition of epinephrine secretion in all rats except the 
female WKY. The importance of this observation was not clear, 
since the role of epinephrine in the pathogenesis of hypertension 
is not really known. However, a failing α2AR-mediated inhibition 
of adrenal epinephrine release has been shown to increase the 
concentration of circulating catecholamines with a detrimental 
effect on the outcome of myocardial infarction in mice (20). It 
may be assumed that an improved α2AR control of adrenal cat-
echolamine release after β1AR-blocker may be beneficial from the 
viewpoint of lowering catecholamine release.
FigUre 8 | The effect of losartan combined with atenolol on total 
peripheral vascular resistance (TPr) response to tyramine-induced 
norepinephrine release in female normotensive (WKY) and 
spontaneously hypertensive rats (shr). Baselines prior to tyramine are 
shown in Table 2. Significant responses (one-sample Student’s t-tests,  
* within symbol) and group differences (two-sample Student’s t-tests) were 
located as indicated at 4 min (peak response, * in brackets left of curves) and 
at 15 min (* in brackets right of curves). Comparisons were made between 
corresponding control and losartan + atenolol-treated groups. *P ≤ 0.025 
after curve evaluations using Repeated Measures Analyses of Variance and 
Covariance (see Materials and Methods).
TaBle 3 | Tyramine-induced salivation in female rats.
Pretreatment normotensive  
rats (WKY) (μl)
spontaneously hypertensive 
rats (shr) (μl)
PBS 24 ± 7 16 ± 4
Atenolol 0 ± 0* 0 ± 0*
Metoprolol 0 ± 0* 0 ± 0*
ICI-118551 18 ± 9 6 ± 1
Nadolol 2 ± 2* 0 ± 0*
L-659,066 9 ± 2 11 ± 3
Atenolol + L-659,066 0 ± 0* 0 ± 0*
ICI-118551 + L-659,066 3 ± 3* 3 ± 2*
Nadolol + L-659,066 0 ± 0* 2 ± 2*
Losartan + atenolol 0 ± 0* 0 ± 0*
Comparisons were made between the PBS control and the experimental groups within 
each strain (*). The difference between the WKY and SHR control groups was not 
statistically significant. *P ≤ 0.05.
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vasodilation, which clearly opposed the NE-induced vaso-
constriction in female WKY. However, the TPR response to 
tyramine in female WKY pretreated with nadolol + L-659,066 
was far less than that after nadolol alone, suggesting that α2AR 
may mediate vasoconstriction also through a mechanism other 
than inhibition of the βAR-adenylyl cyclase stimulation. On 
the other hand, L-659,066 did not lower the enhanced TPR 
response to tyramine after nadolol in female SHR. It there-
fore seemed that α2AR-mediated vasoconstriction depended 
exclusively on βAR-mediated vasodilation as a substrate in the 
female SHR.
β1- and β2AR-selective antagonists alone had no significant 
effect on the TPR response to tyramine in female rats of either 
strain. The same was seen in the presence of L-659,066, except 
for a slight counteracting effect of atenolol (β1) in female WKY. 
These observations indicated that in female rats of both strains 
one βAR-subtype may substitute for the other and that the β1AR 
had a slightly stronger impact than the β2AR. Thus, in both strains, 
both βAR-subtypes had to be blocked to fully eliminate the βAR-
mediated vasodilatory component, which opposed the NE-induced 
vasoconstriction, regardless of the presence of L-659,066.
βar- and α2ar-Mediated control  
of Vascular Tension in Female rats 
compared to That Previously Observed  
in Male rats
In male rats, βAR opposed the TPR response throughout the 
tyramine-infusion period in WKY but downregulated the TPR 
response only during the late part of the infusion period in SHR 
(15). Thus, βAR-mediated vasodilatation played an important 
role in modulating the TPR response throughout the tyramine-
infusion period in both genders in WKY and also in female SHR 
but played a delayed role in downregulating NE-induced vaso-
constriction and TPR in male SHR. This βAR-mediated vasodila-
tory component may provide protection against development of 
hypertension in the female SHR, as observed in premenopause 
women (10).
Similar to that in female WKY (present study), the α2AR-
antagonist L-659,066 eliminated the vasoconstrictory TPR 
response to tyramine also in male WKY (3, 4). Nadolol reversed 
only in part the reduction observed in male WKY (6), different 
from the full counteraction seen in the female WKY (present 
study). Thus, the βAR-mediated vasodilation unshielded by 
α2AR inhibition was more efficient in the female than in the male 
WKY. However, different from the reduced TPR response after 
pretreatment with L-659,066 seen in the female SHR, L-659,066 
had little effect on the TPR response to tyramine in the male SHR, 
and nadolol did not alter the TPR response in L-659,066-treated 
male SHR (6). It therefore seemed that α2AR-mediated vasocon-
striction depended exclusively on βAR-mediated vasodilation as 
a substrate in the female SHR, whereas the α2AR/βAR interaction 
was totally absent in male SHR.
The ability of female rats of both genders to substitute the effect 
of one βAR-subtype with that of the other and thus counteract the 
TPR response to NE was not observed in male rats. In male rats, 
β1-, β2-, and β1+2AR-antagonists all increased the immediate and 
βar- and α2ar-Mediated control of 
Vascular Tension in Female rats
In female rats, βAR-mediated vasodilatation downregulated 
the vasoconstrictory TPR response to tyramine-stimulated NE 
release in both strains. This was indicated by the greatly enhanced 
TPR response throughout the tyramine-infusion period after 
pretreatment with the peripherally restricted β1+2AR-antagonist 
nadolol. The effect of nadolol was greater in WKY than in SHR, 
but still a clear effect of nadolol was observed in the female SHR.
The α2AR-antagonist L-659,066 reversed the vasoconstric-
tory TPR response to tyramine to a vasodilatory response in 
female WKY and eliminated the vasoconstriction in the female 
SHR. Nadolol fully reversed this reduction in TPR in female 
WKY. Inhibition of α2AR therefore unshielded a βAR-mediated 
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late TPR response in WKY and the late response in SHR, with 
little difference between the different antagonists (15). Similarly, 
there was no difference in the impact of the β1-, β2-, and β1+2AR-
antagonists in male WKY in the presence of L-659,066 (6). Thus, 
in the males, both β1and2AR may contribute to the vasodilatation, 
but one subtype did not substitute for the other and the two 
subtypes did not have an additive effect.
The impact on the MBP response to 
Tyramine in Female rats compared to 
That Previously Observed in Male rats
The importance of the βAR-mediated vasodilatory component in 
counteracting the BP response to NE in the female rats was clearly 
demonstrated by the augmented MBP response to tyramine after 
nadolol, and the effect of nadolol was far greater in WKY than 
in SHR. Like for TPR, β1- and β2AR-selective antagonist had no 
significant effect on the MBP response, explained by the ability 
of the two βAR-subtypes to substitute for one another. L-659,066 
lowered the MBP response to tyramine in both strains in female 
rats. In the male rats (4), L-659,066 reduced the response in WKY 
whereas the reduction was not statistically significant in SHR.
The β1ar–aT1r interaction in the control 
of TPr in Female rats compared to That 
Previously Observed in Male rats
Losartan alone (3), like atenolol alone, did not alter the TPR 
response to tyramine-induced NE release in female rats of either 
strain. However, the combination of the two greatly enhanced 
the TPR response in the female WKY, similar to that previously 
observed in male rats of both genders (5). This increased TPR 
response was likely to result from an increased α1+2AR and 
β1AR control of vascular tension in the absence of angiotensin 
II-AT1R-mediated vasoconstriction. However, in the female SHR, 
losartan + atenolol reduced the TPR-peak response to tyramine. 
The mechanism underlying this observation was not clear.
The role of βar and α2ar in the  
control of hr
As in male rats (15), pretreatment with β1AR-antagonists almost 
totally eliminated the tyramine-induced tachycardia in female 
WKY and SHR, whereas β2AR-antagonist had no effect. This 
pattern was not different after additional pretreatment with 
L-659,066 or losartan. These observations showed, as expected, 
that the β1AR dominated the control of HR.
The role of βar and α2ar in  
Tyramine-induced salivation
Salivation does not occur in the anesthetized rat unless stimu-
lated, here by the tyramine-induced release of NE. The salivation 
was mediated through β1AR since it was eliminated in all groups 
given β1AR-antagonist as part of the pretreatment in both strains. 
The same was observed in male rats (T. Berg, unpublished data). 
Since β1AR-antagonists are first-line medications in the treat-
ment of hypertension and cardiac disease, their inhibitory effect 
on salivation may have deleterious effects on salivary secretion 
and, thus, oral health. Indeed, xerostomia, hypo-salivation, 
increased microbiota, and the number of lost teeth were higher 
in patients on antihypertensive medication than in controls (21). 
This problem should be given attention particularly in patients 
on β1-blockers in the form of ascertaining adequate oral hygiene.
summary and implications
The present method using tyramine to stimulate the release of 
NE, allowed a simultaneous study of the effect of βAR and α2AR 
on presynaptic control of catecholamine release and vascular 
tension. The amount of catecholamines released was most likely 
much higher than that needed for a full cardiovascular response. 
Antagonist-induced differences in the TPR response therefore 
most likely reflected changes due to inhibition of the postsynaptic 
receptors rather than drug-induced differences in catecholamine 
release.
The results showed that βAR facilitated tyramine-stimulated 
NE release in both strains in female rats, similar to previously 
observed in male rats, and with a greater effect of the β1- than 
the β2-subtype in all rats but the male SHR, where the effect of 
the two subtypes did not differ. α2AR-mediated inhibition of NE 
release did not interfere with βAR-mediated facilitation of release 
in female rats of both strains or in male WKY, whereas β1AR 
strongly opposed α2AR-auto-inhibition of NE release in male SHR. 
Furthermore, βAR, again with a greater effect of the β1- than the 
β2-subtype, opposed α2AR-mediated auto-inhibition of the secre-
tion of epinephrine in all rats except the female WKY. The role of 
β1AR in catecholamine release is therefore likely to be important 
for the antihypertensive effect of β-blockers in both genders. This 
effect may also have an important therapeutic effect in myocardial 
ischemia where hypoxia may cause massive release of NE release 
through NET (12), similar to that induced by tyramine.
It was further concluded that in both genders in WKY and in 
the female but not in the male SHR, vasoconstrictory α2AR and 
vasodilatory β1+2AR reciprocally modulated the α1AR-mediated 
vasoconstriction activated by the tyramine-stimulated release of 
NE. These results paralleled the observed differences in starting 
BP in these age-matched rats, with normal BP in both genders 
in WKY (SBP/DBP = 85/60 and 103/73 mm Hg in female and 
male WKY, respectively), a moderate hypertension in the female 
SHR (138/103 mm Hg), and a strongly elevated BP in the male 
SHR (183/146 mm Hg) (present results for female rats, and (3) 
for male rats). These results suggested that the females carried 
a βAR-mediated vasodilatory protection against NE-induced 
vasoconstriction, which may play a role in maintaining a lower 
BP in the female gender, even when prone to hypertension as 
the female SHR. This conclusion is in accordance with the fact 
that the positive correlation between MSNA and TPR observed in 
young men was detected in young females only in the presence of 
the non-selective βAR antagonist propranolol (10). Furthermore, 
forearm vasoconstriction in response to infused NE was greater 
in young men than in young women, but after βAR-blockade 
with propranolol, the vasoconstriction was greater in the women 
(22). Also the sensitivity to β2AR agonist was found to be greater 
in women than in men. The mechanisms underlying enhanced 
βAR-dependant vasodilatation in the female are not known. 
Hormones such as estrogen or progesterone may play a role 
(23, 24), but other agents may be involved, such as the angiotensin 
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AT2 receptor (25). However, it should also be pointed out that 
βAR-mediated vasodilatation is opposed by α2AR-mediated 
vasoconstriction. This interaction is evidently sensitive to both 
strain and gender, from being fully dysfunctional in the male SHR 
to giving an α2AR-induced vasoconstriction even in the presence 
of β1+2AR-blockade in the female WKY, with more or less an equal 
balance between the impact of the α2AR and βAR in female SHR 
and male WKY. Estrogen has been shown to mobilize one of the 
three α2AR-subtypes, i.e., α2CAR, to the surface in VSMC from 
human, cutaneous arterioles (26), and this may influence the 
response to NE. The rise in TPR in response to a α2CAR-selective 
agonist was highly variable in female rats but not male rats (3, 11), 
possibly due to differences in the estrous cycle. It is therefore pos-
sible that a change in α2AR functionality is the primary change 
in the gender-dependent difference in the α2AR/βAR control of 
vascular tension.
In the case that βAR-mediated control of TPR and BP is 
the same in young women as in the young female SHR; some 
deductions may be made, which may have therapeutic implica-
tions. Since L-659,066 reduced the TPR response to tyramine-
induced NE release by enhancing βAR-mediated control of 
TPR in the female but not male SHR, a peripherally restricted 
α2AR-antagonist like L-659,066 may represent a favorable, 
antihypertensive medication for women. It is important that 
the α2AR-antagonist should not cross the blood–brain barrier, 
since α2AR-agonists such as clonidine, through its central action 
and inhibition of central sympathetic output, are highly effec-
tive antihypertensive medication. A centrally active antagonist 
may interfere with this antihypertensive mechanism. Since 
one βAR-subtype may substitute for the other in the female 
SHR, L-659,066 may be given as an additive to β1AR-blocker. 
A non-selective βAR-antagonist will block any residual βAR-
vasodilatation and should therefore be avoided. However, 
some caution may be in place regarding this combination 
since L-659,066 combined with atenolol greatly increased the 
level of circulating epinephrine. The consequences of that, for 
instance on cardiac function, is not known. In female SHR, losar-
tan + atenolol had little effect on the TPR response to tyramine 
(present results) but strongly enhanced the vasoconstriction in 
male rats of both genders (5). It may therefore be suggested that 
such combination therapy may enhance adrenergic vasoconstric-
tion to a greater extent in men than in women.
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